MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pum…

Updated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic ...
MPR

Afrezza Label Update Clarifies Transition From SC to Inhaled Mealtime Insulin

Afrezza is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus.
Stocktwits on MSN

Why did MNKD stock jump over 7% in pre-market today?

Shares of MannKind Corp. (MNKD) gained more than 7% in pre-market trading on Monday after the company announced that the U.S. Food and Drug Administration (FDA) approved an update to the prescribing ...

MannKind stock rises after FDA approves updated Afrezza label

Investing.com -- MannKind Corporation (NASDAQ:MNKD) stock rose 3.5% Monday after the company announced that the U.S. Food and Drug Administration (FDA) approved an update to the prescribing ...
InvestorsHub on MSN

MannKind shares climb after FDA clears revised Afrezza prescribing label

MannKind Corporation (NASDAQ:MNKD) shares gained 3.5% on Monday after the company said the U.S. Food and Drug Administration ...